Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 15/20 | 0.64 |
| ▸ | FEN1 | P39748 | 14/20 | 0.64 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA6 | P23280 | 2/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
| ▸ | F10 | P00742 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3828691 | 0.86 | ALOX5AP (0.61) | ALOX5APFEN1 | |
| SCHEMBL6589418 | 0.86 | ALOX5AP (0.51) | ALOX5APFEN1 | |
| Hydrochloric Acid SCHEMBL7230267 | 0.84 | ALOX5AP (0.60) | ALOX5APFEN1 | |
| SCHEMBL6236983 | 0.83 | ALOX5AP (0.62) | ALOX5APFEN1 | |
| SCHEMBL6185772 | 0.82 | ALOX5AP (0.51) | ALOX5APFEN1CA12CA1CA2 | |
| SCHEMBL8658525 | 0.81 | ALOX5AP (0.57) | ALOX5APFEN1F10PTGS1PTGS2 | |
| SCHEMBL6174726 | 0.81 | ALOX5AP (0.50) | ALOX5APFEN1CA12CA1CA2 | |
| SCHEMBL6171447 | 0.81 | ALOX5AP (0.50) | ALOX5APFEN1CA12CA1CA2 | |
| SCHEMBL7265195 | 0.80 | ALOX5AP (0.56) | ALOX5APFEN1F10PTGS1PTGS2 | |
| SCHEMBL6241849 | 0.80 | ALOX5AP (0.50) | ALOX5APFEN1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1465864-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | Warner-Lambert Company LLC (US) | 2004-10-13 | — | — | EP | claimed |
| US-20040167131-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | PFIZER INC. | 2004-08-26 | — | — | US | claimed |
| WO-2003045912-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER-LAMBERT COMPANY LLC (US) | 2003-06-05 | — | — | WO | claimed |
| EP-1539686-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-0991625-B1 | INHIBITORS OF FACTOR XA WITH A NEUTRAL P1 SPECIFICITY GROUP | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040167131-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | PFIZER INC. | 2004-08-26 | — | — | US | disclosed |
| WO-2004024679-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER-LAMBERT COMPANY LLC (US) | 2004-03-25 | — | — | WO | disclosed |
| US-6602895-B2 | Inhibitors of factor Xa with a neutral P1 specificity group | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-05 | — | — | US | disclosed |
| US-20030092740-A1 | Inhibitors of factor Xa with a neutral P1 specificity group | GALEMMO ROBERT A (US) | 2003-05-15 | — | — | US | disclosed |
| US-6403620-B1 | ANTICOAGULANT AGENTS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-11 | — | — | US | disclosed |
| EP-0991625-A2 | INHIBITORS OF FACTOR XA WITH A NEUTRAL P1 SPECIFICITY GROUP | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 2000-04-12 | — | — | EP | disclosed |
| US-5998424-A | ANTICOAGULANTS | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-12-07 | — | — | US | disclosed |
| WO-1998057937-A2 | INHIBITORS OF FACTOR XA WITH A NEUTRAL P1 SPECIFICITY GROUP | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167131-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | TFPI, SERPINC1, F11 | ALOX5AP 1343/4885FEN1 2169/4885CA12 2292/4885 |
| US-20030092740-A1 | Inhibitors of factor Xa with a neutral P1 specificity group | F12, F11, SERPINC1 | ALOX5AP 2758/4885FEN1 821/4885CA12 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.